2:01 PM · 20 December 2024

BREAKING: Novo Nordisk shares lose 20% amid weak performance by CagriSema🚨

Novo Nordisk (NOVOB.DK) shares are losing 20% after the pharmaceutical giant, known for its obesity drugs Ozempic and Wegova, released disappointing clinical trial data for its experimental obesity drug CagriSema. Patients treated with Novo's next-generation weight-loss drug CagriSema lost an average of 22.7% of their weight after 68 weeks, falling short of the 25% goal the drugmaker expected. About 40% of patients lost 25% or more of their body weight.

 

The company's shares are trading at their lowest since August 2023. Source: xStation 

5 October 2026, 1:26 PM

Intel declines: Share in "Terra Fab" threaten?

5 October 2026, 12:38 PM

Market Wrap: France’s Budget, Spain’s Elections. Politics Returns to the Markets

5 October 2026, 11:41 AM

Schneider Electric pays a high price for AI and software growth

2 October 2026, 6:44 AM

Morning wrap: Strong Wall Street, weak Europe and Asia 🚩 NFP to test equity strength

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits